Dr. Drilon on Results of the Phase I/II LIBRETTO-001 Trial

Alexander Drilon, MD
Published: Monday, Sep 09, 2019



Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of  LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers (NSCLC).

To date, the LIBRETTO-001 trial has treated 105 patients across NSCLCs and shows a 68% response rate, with some cases of complete response to selpercatinib.

Drilon says, this trial serves an unmet need in NSCLC, since there is no approved targeted therapy for RET fusion NSCLC.

<<< 2019 World Conference on Lung Cancer


Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of  LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers (NSCLC).

To date, the LIBRETTO-001 trial has treated 105 patients across NSCLCs and shows a 68% response rate, with some cases of complete response to selpercatinib.

Drilon says, this trial serves an unmet need in NSCLC, since there is no approved targeted therapy for RET fusion NSCLC.

<<< 2019 World Conference on Lung Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x